SEC Fo		_										•					
	FORM	4 U	NITI	ED STA	TES	SEC		ES A ngton, E		EXCHAN	NGE (	COM	MISSIO	N	OME	3 APPR	OVAL
to Sec obliga	this box if no l tion 16. Form 4 tions may conti	1 or Form 5	ST										RSHIP	Es	/IB Num timated		3235-0287
Instru	ction 1(b).			Filed	or S	Section	30(h) of the	Investr	nent C	rities Exchang company Act o	e Act of f 1940						
		f Reporting Person <sup>°</sup> ADVISORS I					ame <b>and</b> Tio Pharmae			g Symbol <u>Inc.</u> [ VRC	CA]		. Relationshi Check all app Direc	licable)		.,	Owner
(Last)	(Fi	rst) (l	Middle	)		ate of E		saction	(Mon	th/Day/Year)				er (give tit			r (specify
51 AST	OR PLACE	, 10TH FLOOR			4. lf	Ameno	dment, Date	of Orig	inal Fi	led (Month/Da	y/Year)		. Individual o ine)	r Joint/Gr	oup Fili	ing (Check	Applicable
(Street) NEW Y	ORK N	Y 1	10003											n filed by I		porting Pe an One Re	
(City)	(Si	tate) (i	Zip)		Rı	ule 10	0b5-1(c	) Tra	nsa	ction Ind	icatio	n					
										insaction was m litions of Rule 1				uction or w	ritten pl	an that is ir	ntended to
		Table	e I - N	on-Deriva	ative	Secu	rities Ac	quire	d, Di	sposed of	, or B	enefic	ially Own	ed			
1. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)		ar) 2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)			Benefici	es ally Following	Form	vnership : Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Code	v	Amount	(A) or (D)	Price	Transact (Instr. 3	tion(s)			(1150. 4)
Commor	n Stock			12/27/20	023			Р		79,726	A	\$7.2	(1) 6,85	7,292		Ι	See Footnote <sup>(4)</sup>
Commor	n Stock			12/28/20	023			Р		126,116	A	\$7.08	6,98	3,408		Ι	See Footnote <sup>(4)</sup>
Common Stock				12/29/2023				Р		115,774	A	\$7.24	<sup>(3)</sup> 7,09	9,182		Ι	See Footnote <sup>(4)</sup>
		Та	ble II							posed of, convertib				d			
Derivative Conversion D		Date Exec (Month/Day/Year) if any		Deemed 4. ution Date, Tran		stants, warrants stants de (Instr. de de d		6. Date Exerc Expiration Da (Month/Day/Y		rcisable and Date	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e ( ss   ally   g ( 1	10. Ownershij Form: Direct (D) or Indirect (I) (Instr. 4	Beneficia ) Ownershi ct (Instr. 4)
											I I	Amount or Number	1				
					Code	v	(A) (D)	Date Exer	cisable	Expiration Date	I I	of Shares					
		f Reporting Person <sup>*</sup> ADVISORS I															
(Last) 51 AST	OR PLACE	(First) , 10TH FLOOR		Viddle)													
(Street) NEW Y	ORK	NY	1	0003													
(City)		(State)	(2	Zip)													
	EPTIVE I	f Reporting Person <sup>*</sup> LIFE SCIENC		<u>MASTE</u>	<u>R</u>												
(Last) 51 AST	OR PLACE	(First) , 10TH FLOOR		Viddle)													
(Street)	ODV			0002													

NEW YORK	NY	10003			
(City)	(State)	(Zip)			

1. Name and Address of Reporting Person\*

EDELMAN JOSEPH					
(Last)	(First)	(Middle)			
51 ASTOR PLA	CE, 10TH FLOC	DR			
(Street)					
NEW YORK	NY	10003			
(City)	(State)	(Zip)			

## Explanation of Responses:

1. The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$6.90 to \$7.50 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number shares purchased at each separate price within such range.

2. The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$6.76 to \$7.30 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number shares purchased at each separate price within such range.

3. The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$7.02 to \$7.32 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number shares purchased at each separate price within such range.

4. The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of the Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

/s/ Joseph Edelman - for Perceptive Life Sciences Master Fund Ltd., By: Perceptive Advisors LLC, its 12/29/2023 investment manager, By: Joseph Edelman, its managing member /s/ Joseph Edelman - for Perceptive Advisors LLC, By: 12/29/2023 Joseph Edelman, its managing member /s/ Joseph Edelman 12/29/2023 \*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.